Sign in with Google. Opens in new tab
bullish
Astellas (4503) Implications of Ogeda Acquisition
409 Views06 Apr 2017 10:22
At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
- FWD Group (1828 HK): Offering Details & Index Entry Timeline
- Santos (STO AU): Why FIRB Should Block ADNOC's Takeover
- Xero (XRO AU): Index Flows Following the Capital Raise
- PointsBet (PBH AU): Betr's "Superior Offer"? In An Alternate Reality
Top Unpaywalled Insights
More »- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Astellas (4503) Implications of Ogeda Acquisition06 Apr 2017
- Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm23 Aug 2016
- Implications for Astellas as Medivation Invites Offers02 Aug 2016
x